Dr Polascik on an AI-Driven Urine Volatile Compound Profiling Approach for Prostate Cancer Detection
Thomas J. Polascik, MD, discusses findings from a study of an AI-based VOC assay for prostate cancer detection.
Thomas J. Polascik, MD
Advertisement
Articles by Thomas J. Polascik, MD
Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
2
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
3
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
4
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
5